# Protecting From Pneumococcus in Early Life (The PROPEL Trial)

> **NCT02628886** · PHASE3 · UNKNOWN · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 600 (estimated)

## Conditions studied

- Pneumonia

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid
- **BIOLOGICAL:** placebo 0.9% sodium chloride plus tetanus toxoid
- **OTHER:** tetanus toxoid

## Key facts

- **NCT ID:** NCT02628886
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-11
- **Primary completion:** 2019-02-19
- **Final completion:** 2020-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628886, "Protecting From Pneumococcus in Early Life (The PROPEL Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02628886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*